SRTS Insider Trading

Insider Ownership Percentage: 9.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $123,415.83

Sensus Healthcare Insider Trading History Chart

This chart shows the insider buying and selling history at Sensus Healthcare by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Sensus Healthcare Share Price & Price History

Current Price: $4.77
Price Change: Price Increase of +0.08 (1.71%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for SRTS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$4.77Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Sensus Healthcare (NASDAQ:SRTS)

25.30% of Sensus Healthcare stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SRTS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$3.51Mbought$766ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
Sensus Healthcare logo
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Read More on Sensus Healthcare

Today's Range

Now: $4.77
Low: $4.57
High: $4.77

50 Day Range

MA: $5.63
Low: $4.35
High: $8.99

52 Week Range

Now: $4.77
Low: $3.09
High: $9.33

Volume

130,239 shs

Average Volume

307,590 shs

Market Capitalization

$78.68 million

P/E Ratio

11.93

Dividend Yield

N/A

Beta

1.28

Who are the company insiders with the largest holdings of Sensus Healthcare?

Sensus Healthcare's top insider shareholders include:
  1. Joseph C Sardano (CEO)
  2. Samuel O'rear (Director)
  3. John Heinrich (Director)
  4. Michael Sardano (General Counsel)
Learn More about top insider investors at Sensus Healthcare.

Who are the major institutional investors of Sensus Healthcare?

Sensus Healthcare's top institutional investors include:
  1. Renaissance Technologies LLC — 2.63%
  2. Dimensional Fund Advisors LP — 2.31%
  3. Arrowstreet Capital Limited Partnership — 0.92%
  4. Marshall Wace LLP — 0.81%
  5. O Shaughnessy Asset Management LLC — 0.57%
  6. EAM Investors LLC — 0.56%
Learn More about top institutional investors of Sensus Healthcare stock.

Which major investors are selling Sensus Healthcare stock?

Within the last quarter, SRTS stock was sold by these institutional investors:
  1. Two Sigma Advisers LP
  2. Two Sigma Investments LP
  3. Cubist Systematic Strategies LLC
  4. Occudo Quantitative Strategies LP
  5. EAM Investors LLC
  6. Mindset Wealth Management LLC
  7. Hillsdale Investment Management Inc.
  8. Citadel Advisors LLC

Which major investors are buying Sensus Healthcare stock?

In the last quarter, SRTS stock was acquired by institutional investors including:
  1. Dimensional Fund Advisors LP
  2. Arrowstreet Capital Limited Partnership
  3. Marshall Wace LLP
  4. Millennium Management LLC
  5. OMERS ADMINISTRATION Corp
  6. Squarepoint Ops LLC
  7. O Shaughnessy Asset Management LLC
  8. Integrated Quantitative Investments LLC
Within the previous year, these company insiders have bought Sensus Healthcare stock:
  1. Joseph C Sardano (CEO)
  2. Samuel O'rear (Director)
  3. John Heinrich (Director)
  4. Michael Sardano (General Counsel)
Learn More investors buying Sensus Healthcare stock.